Goldman Sachs Removes Alexion Pharmaceuticals (ALXN) from Conviction Buy List

Goldman Sachs removed Alexion Pharmaceuticals (NASDAQ: ALXN) from its Conviction Buy List, but is keeping a Buy rating and its $112 price target.

The company was replaced on the list with MAKO Surgical (Nasdaq: MAKO), which has greater upside.

Goldman continues to view Alexion as a core holding and remain bullish on the stock as Soliris offers long term sustainable growth and the firm sees solid execution on Soliris and acquisition strategy.

For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $96.32 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• NetEase.com (NTES) PT Raised to $168 at Goldman Sachs
• TD Cowen Downgrades Roots Corp. (ROOT:CN) (RROTF) to Sell
• Deutsche Bank Downgrades Straumann Holding AG (STMN:SW) (SAUHF) to Hold